The efficacy and safety of myo-inositol supplementation for the prevention of gestational diabetes mellitus in overweight and obese pregnant women: A systematic review and meta-analysis
https://doi.org/10.15605/jafes.038.02.11
- Author:
Patricia Ann Factor
1
;
Hannah Corpuz
2
Author Information
1. Department of Obstetrics and Gynecology, University of the Philippines - Philippine General Hospital
2. Department of Internal Medicine, Ilocos Training and Regional Medical Center, San Fernando, La Union, Philippines
- Publication Type:Review
- MeSH:
Diabetes, Gestational;
Obesity;
Inositol Phosphates
- From:
Journal of the ASEAN Federation of Endocrine Societies
2023;38(2):102-112
- CountryPhilippines
- Language:English
-
Abstract:
Background:Myo-inositol has emerged as one of the preventive therapies for the development of gestational diabetes mellitus in at-risk populations. This systematic review and meta-analysis was conducted to determine the efficacy and safety of myo-inositol in decreasing the incidence of gestational diabetes in overweight and obese pregnant women.
Methodology:This meta-analysis was conducted using the standard Cochrane methodology and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) 2020 guidelines. Inclusion criteria were randomized controlled trials (RCTs) that enrolled overweight and obese pregnant women and used myo-inositol supplementation. The primary outcome was the incidence of gestational diabetes mellitus at 24-28 weeks. Secondary outcomes included cesarean section rate, the incidence of pregnancy-induced hypertension, macrosomia and preterm delivery. Risk ratios (RRs) and 95% confidence intervals (CIs) were used for dichotomous data.
Results:Six RCTs were included. Compared to standard micronutrient supplementation, standard dose of myo-inositol (4 g) may reduce the incidence of GDM (RR 0.54; CI [0.30, 0.96]; n = 887 women), but the certainty of evidence is low to very low. With low-dose myo-inositol however, evidence is uncertain about its benefit on the incidence of gestational diabetes mellitus in overweight and obese women with RR 0.71; CI [0.14, 3.50]. No adverse effects were noted. For the secondary outcomes, standard dose myo-inositol appears to reduce the incidence of pregnancy-induced hypertension and preterm delivery, but the certainty of evidence is low to very low.
Conclusion:Current evidence is uncertain on the potential benefit of myo-inositol supplementation in overweight and obese pregnant women. While studies show that 4 g myo-inositol per day may decrease the incidence of GDM, pregnancy-induced hypertension and pre-term birth with no associated risk of serious adverse events, the certainty of evidence is low to very low. Future high-quality trials may provide more compelling evidence to support practice recommendations.
- Full text:2599-Article Text-25117-1-10-20231115.pdf
